International Isotopes Inc. ("International Isotopes" or "INIS") was pleased to announce updated information regarding research it has been funding towards an advanced disease testing procedure for SARS CoV-2, the virus responsible for the COVID pandemic.
International Isotopes has executed an
exclusive licensing agreement with Memorial Sloan Kettering Cancer Center (MSK)
for a patent pending radiolabeled antibody test for detecting SARS-CoV-2. This
information was an update on the first announcement made by the International Isotopes on January 21,
2021, that it had been funding the research and development of an advanced
COVID test at a leading research hospital.
In early 2021, INIS and MSK entered into a
sponsored research agreement to further advance and develop research being
conducted at MSK using radiolabeled antibodies to develop an accurate,
inexpensive, portable, high volume, rapid and non-invasive saliva-based testing
kit to detect SARS CoV-2. While the initial research focused on SARS-CoV-2
detection, INIS plans to support additional research and development to apply
the new testing method to other viruses.
To
read more please visit:
Source: CISION